ACM
XLO icon

ADAR1 Capital Management’s Xilio Therapeutics XLO Stock Holding History

ADAR1 Capital Management’s Portfolio XLO Stock Details XLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-2,857
Closed -$29K – 239
2025
Q1 		$29K Buy
+2,857
New +$35.9K 0.01% 190
2024
Q3 		– Sell
-107
Closed -$1.42K – 349
2024
Q2 		$1.42K Buy
+107
New +$1.68K ﹤0.01% 258

Other funds holding XLO

GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
MC
Merck & Co Kenilworth, New Jersey $349M AUM 146.07% 1-Year Est. Return
TPC
Takeda Pharmaceutical Company Tokyo, Japan $16.4M AUM 195.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
GCM
Ghisallo Capital Management Boston, Massachusetts $3.63B AUM 30.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIIC
AJU IB Investment Company Seoul, South Korea $30.5M AUM 128.96% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

ADAR1 Capital Management's XLO Position: Q2 2025 in Review

ADAR1 Capital Management sold out of Xilio Therapeutics (XLO) in Q2 2025, closing a stake of 2,857 shares — an estimated $29K sold.

ADAR1 Capital Management first reported a position in XLO in Q2 2024 and held it in 2 quarters. The position peaked at $29K in Q1 2025. 35 funds tracked by Wall St. Rank hold XLO as of Q2 2025.

  • ADAR1 Capital Management reported no remaining Xilio Therapeutics position as of Q2 2025 after selling out during the quarter.
  • ADAR1 Capital Management sold 2,857 Xilio Therapeutics shares in Q2 2025, an estimated $29K.
  • ADAR1 Capital Management first reported a position in Xilio Therapeutics in Q2 2024 and held it in 2 quarters.
  • ADAR1 Capital Management's Xilio Therapeutics position peaked at $29K in Q1 2025.
  • 35 funds tracked by Wall St. Rank held Xilio Therapeutics as of Q2 2025.

Based on ADAR1 Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.